Hospital Acquired Infections Diagnostics Market Size & Growth Forecast 2026–2035, By Segments (Infection, Test, Product, Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Hospital Acquired Infections Diagnostics Market size was estimated at USD 4.92 Billion in 2025 and is projected to grow at a 7.3% CAGR from 2026 to 2035, exceeding USD 9.95 Billion by 2035. The industry revenue for 2026 is assessed at USD 5.24 billion.

• Base Year Value (2025): USD 4.92 Billion
• CAGR (2026-2035): 7.3%
• Forecast Year Value (2035): USD 9.95 Billion
• Historical Data Period: 2022-2025
• Largest Region: Europe
• Forecast Period: 2026-2035

Hospital Acquired Infections Diagnostics Market Intelligence Snapshot:

• Regional Market Dynamics:

  • Europe leads due to established hospital laboratory infrastructure, standardized infection surveillance protocols, and routine integration of diagnostics into inpatient workflows supporting early pathogen detection and outbreak control.
  • Asia Pacific is expanding at 8.25% CAGR, driven by growing hospital capacity, stronger infection prevention focus, and wider adoption of diagnostic platforms for faster pathogen detection and surveillance.

• Segment Momentum:

  • UTI accounted for 28.94% of the market in 2025, supported by frequent screening requirements, recurrent inpatient testing, and the need for rapid infection identification to support treatment and infection control.
  • Molecular testing leads and grows fastest because hospitals increasingly prioritize rapid turnaround and accurate pathogen detection, enabling quicker clinical decisions and more effective infection management.

• Market Expansion Drivers:

  • Rising prevalence of hospital-acquired infections and antimicrobial resistance increasing diagnostic demand.
  • Expansion of molecular diagnostics like PCR enabling rapid pathogen detection and treatment optimization.
  • Growing surgical procedures and aging population increasing hospital infection screening requirements.

• Leading Market Participants:

  Leading players in the hospital acquired infections diagnostics market include bioMérieux S.A. (France), Abbott Laboratories (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Becton, Dickinson and Company (United States), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (United States), Hologic, Inc. (United States), Siemens Healthineers AG (Germany), Meridian Bioscience, Inc. (United States), Danaher Corporation (United States).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 4.92 Billion
  • 2026 Market Size: USD 15.2 billion
  • Projected Market Size: USD 9.95 Billion by 2035
  • Growth Forecasts: 7.3% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: Europe
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: UTI (Infection) | Molecular (Test) | Consumables (Product) | Blood Tests (Type)
  • Emerging Opportunity Segment: UTI (Infection) | Molecular (Test) | Consumables (Product) | Blood Tests (Type)

Market Growth Drivers and Industry Trends

Rising prevalence of hospital-acquired infections and antimicrobial resistance increasing diagnostic demand

As hospitals face a higher burden of healthcare-associated infections alongside more resistant bacterial strains, clinicians are under greater pressure to identify pathogens quickly and distinguish routine cases from those requiring targeted isolation and therapy. This is increasing demand for the hospital acquired infections diagnostics market because delayed or empirical treatment carries higher clinical and operational costs, including longer stays, infection spread, and ineffective antibiotic use. Antimicrobial resistance makes broad-spectrum prescribing less reliable, so providers are relying more heavily on diagnostic confirmation to guide stewardship decisions, prioritize infection control measures, and support earlier intervention in high-risk care settings.

Expansion of molecular diagnostics like PCR enabling rapid pathogen detection and treatment optimization

The spread of PCR and related molecular platforms is supporting market development by shifting hospital infection diagnostics away from slower culture-dependent workflows toward faster, clinically actionable results. In the hospital acquired infections diagnostics market, this changes purchasing and adoption behavior because laboratories and care teams can detect specific pathogens and resistance markers earlier, allowing treatment adjustments before complications escalate or unnecessary antibiotics are continued. The practical effect is not just faster testing, but greater integration of diagnostics into real-time clinical decision-making, especially where turnaround time directly affects isolation protocols, ICU management, and antimicrobial stewardship performance.

Growing surgical procedures and aging population increasing hospital infection screening requirements

Higher surgical volumes and an expanding elderly patient base are reinforcing market demand by increasing the number of patients who require infection risk assessment before, during, and after hospitalization. Older adults and post-surgical patients often present with weaker immune response, more comorbidities, greater device use, and longer inpatient stays, all of which raise the likelihood of suspected hospital-acquired infection and the need for diagnostic evaluation. This is contributing to market size growth in the hospital acquired infections diagnostics market as hospitals broaden screening intensity in perioperative pathways, critical care, and recovery settings where early detection helps prevent escalation into more complex and costly care episodes.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising prevalence of hospital-acquired infections and antimicrobial resistance increasing diagnostic demand	2.20%	High	North America, Europe	High	Near Term
Expansion of molecular diagnostics like PCR enabling rapid pathogen detection and treatment optimization	2.00%	High	Europe, North America, Asia Pacific	High	Near Term
Growing surgical procedures and aging population increasing hospital infection screening requirements	1.60%	High	Asia Pacific, Europe	Medium	Mid Term

Regional Demand Dynamics

Europe (Largest Region) vs Asia Pacific (Fastest-Growing Region)

Europe held the largest regional share of the hospital acquired infections diagnostics market in 2025, supported by the region’s established hospital laboratory infrastructure, broad use of standardized infection surveillance protocols, and strong integration of diagnostic testing into inpatient care workflows. Demand is aided by the practical need for early identification of healthcare-associated pathogens in acute care settings, where infection control teams, microbiology labs, and hospital administrators rely on routine and confirmatory testing to manage outbreak risks, support antimicrobial stewardship, and meet clinical quality requirements. The region’s leadership is supported by the consistent use of diagnostics across mature healthcare systems where testing is embedded in day-to-day hospital operations rather than adopted only in response to severe infection events.

Asia Pacific is projected to register an 8.25% CAGR over the forecast period in the hospital acquired infections diagnostics market, driven by expanding hospital capacity, rising attention to infection prevention, and wider adoption of modern diagnostic platforms in high-volume care settings. Growth is accelerating as healthcare providers across the region strengthen laboratory capabilities to detect hospital-linked infections more quickly, particularly where increasing patient volumes and more complex inpatient procedures are creating greater pressure for timely surveillance and pathogen identification. Adoption is also being propelled by the operational need to reduce treatment delays and improve infection control practices in fast-developing healthcare systems.

Regional Market Attractiveness & Strategic Fit Matrix
Parameter	North America	Asia Pacific	Europe	Latin America	MEA
Innovation Hub	Advanced	Developing	Advanced	Developing	Nascent
Cost-Sensitive Region	Low	Medium	Low	High	High
Regulatory Environment	Supportive	Restrictive	Supportive	Neutral	Neutral
Demand Drivers	Strong	Moderate	Strong	Weak	Weak
Development Stage	Developed	Developing	Developed	Developing	Emerging
Adoption Rate	High	Medium	High	Low	Low
New Entrants / Startups	Dense	Moderate	Dense	Sparse	Sparse
Macro Indicators	Strong	Stable	Strong	Stable	Weak

Key Country Insights

United States

Clinical Surveillance Focus

The U.S. continues to prioritize rapid hospital-acquired infection diagnostics through expanded laboratory automation, antimicrobial stewardship programs, and infection surveillance initiatives. Healthcare providers across the U.S. increasingly integrate molecular testing and data-driven monitoring to strengthen patient safety and improve clinical decision-making.

Japan

Precision Infection Control

Japan focuses on highly accurate diagnostic technologies that complement stringent hospital infection prevention standards. Clinical laboratories in Japan are adopting advanced molecular and automated testing platforms to improve turnaround times and support effective infection control strategies.

South Korea

Digital Diagnostics Adoption

South Korea is strengthening hospital infection diagnostics through digital laboratory infrastructure and advanced molecular testing capabilities. Healthcare providers in South Korea increasingly combine automation with real-time surveillance tools to improve detection efficiency and clinical response.

Germany

Laboratory Quality Integration

Germany emphasizes standardized diagnostic workflows and high-quality microbiology practices across hospitals. Healthcare institutions in Germany continue investing in precise pathogen identification and antimicrobial resistance detection to support infection prevention protocols and efficient clinical management.

France

Healthcare Safety Enhancement

France continues expanding diagnostic capabilities that reinforce infection prevention within hospitals and specialized care facilities. Healthcare organizations in France prioritize reliable laboratory testing and coordinated surveillance to support clinical quality improvement and regulatory compliance.

Italy

Hospital Testing Modernization

Italy is modernizing hospital diagnostic laboratories to improve identification of healthcare-associated infections and antimicrobial resistance. Clinical facilities across Italy are adopting automated workflows and standardized testing approaches to strengthen infection management practices.

Segment Leadership and Growth Trends

  Infection Segment Analysis: UTI (Largest & Fastest-Growing Segment)

UTI accounted for a 28.94% share of the hospital acquired infections diagnostics market in 2025, making it both the leading and the fastest-growing infection segment. This position is backed by the high diagnostic attention given to catheter-associated and other facility-linked urinary infections, where timely identification is critical for treatment decisions and infection control. UTI continues to gain momentum in the hospital acquired infections diagnostics market because routine screening needs, recurrent testing in inpatient settings, and the need to distinguish infection sources quickly make this segment a consistent priority for hospitals and diagnostic laboratories.

Test Segment Analysis: Molecular (Largest & Fastest-Growing Segment)

Molecular held the largest share of the hospital acquired infections diagnostics market in 2025 and also remained the fastest-growing test segment. Its leadership is driven by the practical need for rapid and accurate pathogen detection in hospital settings, where clinicians must act quickly to manage infection spread and guide therapy. Growth in the molecular segment continues to outpace alternatives in the hospital acquired infections diagnostics market because healthcare providers increasingly rely on faster turnaround and more precise diagnostic confirmation when addressing hospital-acquired infection risks.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Infection	UTI, Pneumonia, Surgical Site Infection, Bloodstream Infections, Others	UTI	UTI
Test	Molecular, Conventional	Molecular	Molecular
Product	Consumables, Instruments	Consumables	Consumables
Type	Blood Tests, Urinalysis	Blood Tests	Blood Tests

Competitive Landscape and Market Positioning

Key companies in the hospital acquired infections diagnostics market:

1. bioMérieux S.A. (France)

2. Abbott Laboratories (United States)

3. F. Hoffmann-La Roche Ltd. (Switzerland)

4. Becton Dickinson and Company (United States)

5. QIAGEN N.V. (Netherlands)

6. Thermo Fisher Scientific Inc. (United States)

7. Hologic Inc. (United States)

8. Siemens Healthineers AG (Germany)

9. Meridian Bioscience Inc. (United States)

10. Danaher Corporation (United States)

The hospital acquired infections diagnostics market is advancing through the development of rapid testing platforms and highly sensitive diagnostic technologies designed to improve infection detection accuracy. Companies are investing in molecular diagnostics, automation, and AI-assisted analysis tools to accelerate clinical decision-making and reduce healthcare-associated risks. Growing emphasis on infection control protocols and faster turnaround times continues to drive innovation across diagnostic solutions.

Industry Development/News

Company Name	Date	Key Development
QIAGEN	Nov-24	QIAGEN expanded its diagnostic operational footprint by establishing a new facility in Barcelona, Spain. The site is dedicated to enhancing QIAstat-Dx operations, infectious disease testing, and precision medicine, directly supporting diagnostic development partnerships with Eli Lilly and AstraZeneca.
QIAGEN	Jun-24	QIAGEN launched its FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 in the United States, enabling rapid multiplex detection of up to 16 pathogens. The technological introduction improves diagnostic accuracy and hospital operational efficiency for managing complex gastrointestinal infections.
bioMérieux	Jan-24	bioMérieux acquired Canadian healthcare software firm LUMED to enhance its clinical decision support capabilities. The transaction integrates advanced infection prevention software into bioMérieux's portfolio, optimizing hospital antimicrobial stewardship programs and tracking systems for healthcare-associated infections.
Danaher	Nov-23	Danaher partnered with Oxford University to advance precision medicine for sepsis through rapid molecular testing. The initiative leverages Cepheid's diagnostic technology to identify distinct sepsis subtypes, driving clinical efficiency in critical hospital care environments.
Thermo Fisher Scientific	Feb-23	Thermo Fisher Scientific partnered with Mylab Discovery Solutions to commercialize high-quality RT-PCR infectious disease diagnostic kits in India. The collaboration expands Thermo Fisher's geographic presence and enhances local clinical capacity for molecular diagnostics.